Business
From Hype to P&L: Hospitals Now Buying AI That Pays
VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- USANewsGroup .com Ne...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"From Hype to P&L: Hospitals Now Buying AI That PaysISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.\n\n\n\n VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) --\n \n\n USANewsGroup\n \n\n\n .com\n \n\n News Commentary\n \n – Hospitals running on thin margins are done chasing clinical moonshots\n \n [1]\n \n . They want AI that improves the bottom line. Healthcare AI spending hit $1.4 billion this year, nearly tripling 2024 levels, with 75% of that money coming from health systems desperate to cut costs and stop staff burnout. Predictive AI integrated into hospital EHRs jumped to 71% adoption in 2024, up from 66% the year before, with the fastest-growing use cases in billing automation and revenue cycle management\n \n [2]\n \n . Five companies are leading this \"economic validation\" wave:\n \n VentriPoint Diagnostics\n \n (TSXV: VPT) (OTCPK: VPTDF),\n \n Butterfly Network, Inc.\n \n (NYSE: BFLY),\n \n Hims & Hers Health, Inc.\n \n (NYSE: HIMS),\n \n Clover Health Investments, Corp.\n \n (NASDAQ: CLOV), and\n \n iRhythm Technologies, Inc.\n \n (NASDAQ: IRTC).\n \n\n The market is projected to reach $110.61 billion by 2030, growing at a 38.6% clip from 2025, as ROI-focused tools displace experimental pilots\n \n [3]\n \n . With nearly 40% of hospitals now operating at negative margins, financial pressure is forcing rapid adoption of AI that generates revenue or slashes costs, not just promises better outcomes\n \n [4]\n \n .\n \n\n\n Ventripoint Diagnostics\n \n (TSXV: VPT) (OTCPK: VPTDF)\n \n has appointed\n \n David Swetlow as Chief Financial Officer, effective immediately. The move strengthens the company's leadership team as it works to scale its VMS+ cardiac imaging platform globally. Management views the appointment as a key step in executing a refreshed commercial strategy designed to drive market adoption and revenue growth across key international markets.\n \n\n \"This is a pivotal moment for\n \n Ventripoint\n \n ,\" said Hugh MacNaught, President and CEO of\n \n Ventripoint Diagnostics\n \n . \"David's leadership will play a vital role as we execute on a refreshed commercial strategy designed to scale our technology and platform, strengthen our global partnerships, and position the company for new markets and revenue growth.\"\n \n\n Swetlow brings over 25 years of senior management experience fro...